Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

767 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients With Crohn's Disease: Real-Life Data From the Sicilian Network for Inflammatory Bowel Disease.
Macaluso FS, Fries W, Privitera AC, Cappello M, Siringo S, Inserra G, Magnano A, Di Mitri R, Mocciaro F, Belluardo N, Scarpulla G, Magrì G, Trovatello A, Carroccio A, Genova S, Bertolami C, Vassallo R, Romano C, Citrano M, Accomando S, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Porcari S, Ferracane C, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Diseases [SN-IBD]. Macaluso FS, et al. Among authors: orlando a, orlando r. J Crohns Colitis. 2019 Feb 1;13(2):209-217. doi: 10.1093/ecco-jcc/jjy156. J Crohns Colitis. 2019. PMID: 30295785
Mycophenolate mofetil is a valid option in patients with inflammatory bowel disease resistant to TNF-α inhibitors and conventional immunosuppressants.
Macaluso FS, Maida M, Renna S, Orlando E, Affronti M, Sapienza C, Dimarco M, Orlando R, Rizzuto G, Cottone M, Orlando A. Macaluso FS, et al. Among authors: orlando e, orlando a, orlando r. Dig Liver Dis. 2017 Feb;49(2):157-162. doi: 10.1016/j.dld.2016.10.001. Epub 2016 Oct 14. Dig Liver Dis. 2017. PMID: 27876682
The real-world effectiveness of vedolizumab on intestinal and articular outcomes in inflammatory bowel diseases.
Macaluso FS, Orlando R, Fries W, Scolaro M, Magnano A, Pluchino D, Cappello M, Morreale GC, Siringo S, Privitera AC, Ferracane C, Belluardo N, Alberghina N, Ventimiglia M, Rizzuto G, Renna S, Cottone M, Orlando A. Macaluso FS, et al. Among authors: orlando a, orlando r. Dig Liver Dis. 2018 Jul;50(7):675-681. doi: 10.1016/j.dld.2018.02.013. Epub 2018 Mar 1. Dig Liver Dis. 2018. PMID: 29576495
A real life comparison of the effectiveness of adalimumab and golimumab in moderate-to-severe ulcerative colitis, supported by propensity score analysis.
Renna S, Mocciaro F, Ventimiglia M, Orlando R, Macaluso FS, Cappello M, Fries W, Mendolaro M, Privitera AC, Ferracane C, Pisana V, Magnano A, Pluchino D, Inserra G, Scarpulla G, Garufi S, Carroccio A, Siringo S, Di Mitri R, Cottone M, Orlando A. Renna S, et al. Among authors: orlando a, orlando r. Dig Liver Dis. 2018 Dec;50(12):1292-1298. doi: 10.1016/j.dld.2018.06.008. Epub 2018 Jun 22. Dig Liver Dis. 2018. PMID: 30007516
The SPOSIB SB2 Sicilian Cohort: Safety and Effectiveness of Infliximab Biosimilar SB2 in Inflammatory Bowel Diseases, Including Multiple Switches.
Macaluso FS, Fries W, Viola A, Centritto A, Cappello M, Giuffrida E, Privitera AC, Piccillo G, Magnano A, Vinci E, Vassallo R, Trovatello A, Belluardo N, Giangreco E, Camilleri S, Garufi S, Bertolami C, Ventimiglia M, Renna S, Orlando R, Rizzuto G, Orlando A. Macaluso FS, et al. Among authors: orlando a, orlando r. Inflamm Bowel Dis. 2021 Jan 19;27(2):182-189. doi: 10.1093/ibd/izaa036. Inflamm Bowel Dis. 2021. PMID: 32083291
A propensity score weighted comparison of vedolizumab and adalimumab in Crohn's disease.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Sitibondo A, Cappello M, Scrivo B, Busacca A, Privitera AC, Camilleri S, Garufi S, Di Mitri R, Mocciaro F, Belluardo N, Giangreco E, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: orlando a, orlando r. J Gastroenterol Hepatol. 2021 Jan;36(1):105-111. doi: 10.1111/jgh.15107. Epub 2020 Jun 8. J Gastroenterol Hepatol. 2021. PMID: 32428981
A propensity score weighted comparison of Vedolizumab, Adalimumab, and Golimumab in patients with ulcerative colitis.
Macaluso FS, Ventimiglia M, Fries W, Viola A, Cappello M, Scrivo B, Magnano A, Pluchino D, Camilleri S, Garufi S, Mitri RD, Mocciaro F, Magrì G, Ferracane C, Citrano M, Graziano F, Bertolami C, Renna S, Orlando R, Rizzuto G, Cottone M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD).. Macaluso FS, et al. Among authors: orlando a, orlando r. Dig Liver Dis. 2020 Dec;52(12):1461-1466. doi: 10.1016/j.dld.2020.06.014. Epub 2020 Jun 26. Dig Liver Dis. 2020. PMID: 32601033
Effectiveness and safety of vedolizumab in biologically naïve patients: A real-world multi-centre study.
Macaluso FS, Fries W, Renna S, Viola A, Muscianisi M, Cappello M, Guida L, Siringo S, Camilleri S, Garufi S, Privitera AC, Belluardo N, Giangreco E, Bertolami C, Vassallo R, Rizzuto G, Orlando R, Ventimiglia M, Orlando A; Sicilian Network for Inflammatory Bowel Disease (SN-IBD). Macaluso FS, et al. Among authors: orlando a, orlando r. United European Gastroenterol J. 2020 Nov;8(9):1045-1055. doi: 10.1177/2050640620948802. Epub 2020 Aug 9. United European Gastroenterol J. 2020. PMID: 32772830 Free PMC article.
Letter: a prospective real life comparison of the efficacy of adalimumab vs. golimumab in moderate to severe ulcerative colitis.
Renna S, Orlando E, Macaluso FS, Maida M, Affronti M, Giunta M, Sapienza C, Rizzuto G, Orlando R, Dimarco M, Cottone M, Orlando A. Renna S, et al. Among authors: orlando e, orlando a, orlando r. Aliment Pharmacol Ther. 2016 Aug;44(3):310-1. doi: 10.1111/apt.13692. Aliment Pharmacol Ther. 2016. PMID: 27375103 Free article. No abstract available.
767 results